Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) Net Margin (2019 - 2025)

Legend Biotech filings provide 7 years of Net Margin readings, the most recent being 0.82% for Q4 2025.

  • On a quarterly basis, Net Margin fell 3082.0% to 0.82% in Q4 2025 year-over-year; TTM through Dec 2025 was 25.38%, a 3413.0% increase, with the full-year FY2025 number at 3.22%, down 2688.0% from a year prior.
  • Net Margin hit 0.82% in Q4 2025 for Legend Biotech, up from 14.12% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 31.64% in Q4 2024 to a low of 1614.13% in Q2 2022.
  • Median Net Margin over the past 5 years was 92.49% (2024), compared with a mean of 246.31%.
  • Biggest five-year swings in Net Margin: plummeted -116149bps in 2022 and later skyrocketed 134258bps in 2023.
  • Legend Biotech's Net Margin stood at 226.53% in 2021, then plummeted by -117bps to 491.72% in 2022, then soared by 100bps to 0.0% in 2023, then soared by 17358954bps to 31.64% in 2024, then tumbled by -97bps to 0.82% in 2025.
  • The last three reported values for Net Margin were 0.82% (Q4 2025), 14.12% (Q3 2025), and 48.7% (Q2 2025) per Business Quant data.